Other research groups have been examining the interaction of CMTM6 with PD-L1 in cancer cells; they revealed that CMTM6 associates with PD-L1 on the cell surface, reduces its ubiquitination, increases the half-life of PD-L1 [29], and acts to exacerbate anticancer immunity [23]. The gene discussed is CMTM6; the disease is cancer.